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The Art and Science of Infusion Nursing

The Relationship Between Central LineAssociated Bloodstream Infections and
Extended Intravenous Solution Hang Times
Therese B. Mianecki, PhD, RN ● Edward L. Peterson, PhD

ABSTRACT
Central line-associated bloodstream infections (CLABSIs) can result in increased morbidity and mortality and billions
of dollars of costs per year to institutions and patients. Fluctuating availability of manufacturers’ supplies of intravenous (IV) solutions have created issues for health systems in which policy and procedures have been examined
regarding extended hang time for IV solutions. This article examined the relationship between extended hang times
of nonadditive IV solutions and incidence of CLABSIs in intensive and general practice inpatient units in a quaternary
care setting. The incidence of CLABSIs with extended hang times of up to 96 hours, of nonadditive IV solutions, has
demonstrated that significant changes in CLABSIs were not evident.
Key words: catheter-related infections, central line-associated bloodstream infections, CLABSI, cross infection,
equipment contamination, hospital-acquired infection, infection, infusions, intravenous, time factors

H

ospitals can use hundreds of thousands of intravenous (IV) solution bags per day depending on
patient census and acuity. If manufacturer production interruptions occur and trigger supply shortages of small- or large-volume infusates, the subsequent
supply of either size IV bag can also be affected. Supply
issues of sodium chloride and dextrose IV solutions have
occurred intermittently dating back to 2013, when manufacturers began notifying US hospitals that they might
begin experiencing delivery delays.1,2
Periodic shortages of IV solutions were exacerbated
in the summer of 2017 when quality-related production
interruptions occurred at B. Braun Medical. Several months
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later, in September of 2017, Hurricane Maria caused power
interruptions and damage to Baxter International manufacturing plants in Puerto Rico. These situations left 2 of
the 3 major IV solution suppliers unable to meet market
demands and caused critical supply issues for US health
care institutions in early 2018.1-3 The national shortage of
IV solutions in 2018 prompted many health care administrators and supply officers to search for options to meet
the IV fluid needs of patients. Subsequently, many health
care institutions have had to revise policies and procedures
related to how IV solution administration is managed.
This retrospective research study examined changes
in the incidence of central line- associated bloodstream
infections (CLABSIs) after IV solution administration policy
and procedure revisions were triggered by IV solution
shortages. The study took place at an 887-bed, quaternary care hospital located in the Midwestern United States,
where IV solutions were obtained from 3 US manufacturers (Baxter International, B. Braun Medical, and Hospira
Inc) via a distributor. The staff was notified via email
by the chief nursing officer (CNO) when the procedural
change to extend hang times would begin for nonadditive
IV solutions and the reasons for this change. It was also
announced at the monthly patient care services meeting where attendance is required by all nurse managers
and nursing leadership personnel. Clinical nurse staffing
in intensive care units (ICUs) and general practice units
(GPUs) remained consistent before and after the intervention, as did patient census.
j o u rn a l o f i n f u s i o n n u rs i n g. c o m
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BACKGROUND
CLABSIs are grouped under the umbrella of hospital-acquired
infections (HAIs), which can cause significant morbidity and
mortality and billions of dollars of expense each year.4 In
a systematic review by Zimlichman et al,5 estimated costs
per CLABSI were $51,505 per patient and $2.02 billion
annually (converted to today’s dollars), an 18.9% share of
all HAIs. The US Department of Health and Human Services
has made it a priority to reduce HAIs in patients, although
no specific guidelines or standards of practice are evident
regarding hang times of nonadditive IV solutions from the
Centers for Disease Control and Prevention (CDC).6 The
Guidelines for the Prevention of Intravascular CatheterRelated Infections were developed in collaboration with
professional organizations representing various health care
disciplines.7 However, these and other organizations have
not provided specific directives for managing hang times of
nonadditive IV solutions.6-8
Although other studies have examined patient safety
related to lengthening hang times of IV administration sets,
few have examined the relationship between extending the
hang times of nonadditive IV solutions beyond 24 hours
and the incidence of CLABSIs. Investigators who tested IV
solutions for growth found no incidence of microbial colonization in IV fluids after 24-hour hang times.9 To evaluate
whether solutions were contaminated before use, BrockUtne et al10 randomly tested stock IV solution bags (Hospira
Inc, Lake Forest, IL) and noted that no microbial growth was
evident. Other authors have explored tangentially related
issues, such as strategies to decrease CLABSIs after a spike
in incidence,11 as well as negative and positive aspects of
central catheters, and best evidence to avoid CLABSIs.12
Others reported on the establishment of a vascular access
team and provided guidance to decrease central line usage
and incidence of CLABSIs.13 In 2019, Shang et al14 examined
staffing and its relationship to all HAIs, including urinary
tract infections, bloodstream infections, and pneumonias.
Their findings indicated that short staffing was related to
incidence of HAIs.14 In summary, factors related to IV solutions and incidence of CLABSIs have been explored, but no
studies were found that directly examined the relationship
of CLABSI incidence to IV solution hang times of >24 hours
and up to 96 hours. The purpose of this study was to test the
hypothesis that there would be no change in the inpatient
incidence of CLABSIs in ICU or GPU populations when nonadditive IV solution hang times were extended. The study
aim included identifying the incidence of CLABSIs before and
after the time period when IV hang times were extended.

METHODS
The study protocol was reviewed and approved by the hospital institutional review board before project implementation. A retrospective chart review was completed on a
158   Copyright © 2021 Infusion Nurses Society

convenience sample of 2967 inpatients who were admitted
from mid-September 2017 through mid-February 2018.

Data Collection

The data were abstracted electronically and included the variables: length of stay, CLABSI incidence, diagnoses, gender, IV
type and IV hang time in hours, patient care unit, and patient
age at admittance. No formal tools or questionnaires were
used to drive the data abstraction process, but the researchers and a nurse practice expert met with the data abstractor
several times before and during data abstraction to discuss
the aims of the study, define and clarify the variables of
interest, and address related issues. Data were collected for
the comparison and intervention groups over a 2.5-month
time period. The comparison group included ICU and GPU
patients who received nonadditive IV solutions before the
policy change. After a 2-week delay following the policy
change, data collection began for the intervention group that
included ICU and GPU patients who received the same type
of nonadditive solutions. The 2 weeks between policy change
and the beginning of the intervention period allowed time
for the clinical nursing staff to transition to the revised policy.
Nonadditive IV solutions included 0.9% sodium chloride,
dextrose, or lactated Ringer’s solution that are hung for
the purpose of keeping a vein open (KVO) for fluid volume
replacement or for periodic IV-push medication administration. Patients in the ICUs had at least 1 nonadditive IV
solution for the purpose of KVO for IV medication administration or for fluid volume replacement if needed. Patients
on GPUs frequently had nonadditive IV solutions for fluid
replacement, KVO, or IV medications. The standard of care
for patients with central catheters remained consistent
throughout the course of the study for both the intervention and comparison groups. The CDC definition of CLABSI
was used at the study site to define and track the incidence
of CLABSIs.15

Statistical Analysis

For the power characteristics of the analyses, an infection
rate of 0.5% was assumed in the comparison group so
that, with the given sample size, a change to ≥1.5% could
be detected in the intervention group with 80% power
and a 2-sided α level of 0.05. Sample data were analyzed
using SAS, version 9.4 (SAS Institute, Inc, Cary, NC). For the
analyses, nominal variables were examined for differences
between groups using a χ2 test. Continuous variables were
analyzed using the z tests.

RESULTS
The ages of patients within the total sample of 2967
patients ranged from 15 to 101 years. The mean age in the
comparison group was 54.46 ± 18.82 years, and the mean
age in the intervention group was 53.16 ± 19.06 years.
Women composed 59.76% (n = 1773) of the total sample,
Journal of Infusion Nursing
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TABLE 1

Cross-tabulations: Gender by Group Membership
Group
Intervention

Comparison

Total

Gender

N

%

N

%

N

%

Male

774

40.3

420

40.1

1194

40.2

Female

1145

59.7

628

59.9

1773

59.8

Total

1919

100

1048

100

2967

100

and men composed 40.24% (n = 1194) of the total sample
(Table 1).
The comparison of the mean length of stay found that
the comparison group (7.43 ± 8.08 days) was longer than
the intervention group (6.71 ± 7.13 days; P = 0.01). This
difference was statistically significant (Z = 2.46). The average total IV hours did not differ significantly between the
comparison group (n = 757; 45.10 ± 31.06 hours) and the
intervention group (n = 1376; 44.68 ± 28.34 hours). IV
hours were not consistently recorded in all patient charts,
and these missing data in some patient records account for
the decreased sample sizes when examining total IV hours
in the comparison and intervention groups (Table 2).
The number of infections were compared between the
intervention and comparison groups after a retrospective
review of patient records. Based on this review, 5 infections (0.27%) were found in the intervention group, and
2 (0.20%) were found in the comparison group (Table 3).
Because of the small number of infections in the 2 groups,
statistical testing for differences was not conducted.
Although not a specific aim of the study, the admitting diagnoses were obtained for the study participants.
Because of the myriad of diagnoses, with many patients

having multiple comorbidities, an inclusive list was not
completed. Instead, the 3 most noted diagnoses in the 2
groups were determined. Common to both groups was the
diagnosis of sepsis. In the intervention group, 9 participants
(13.6%) in the ICU and 28 (42.4%) in the GPU groups were
diagnosed with sepsis. The comparison group had 4 (6.1%)
in the ICU and 25 (37.9%) in the GPU with this diagnosis.
No other admitting diagnoses were common among the 4
groups. Table 4 presents these diagnoses for the intervention and control groups by ICU and GPU.

DISCUSSION
The study identified incidences of CLABSIs before and after
the time period when IV hang times were extended up to 96
hours. Five infections (0.27%) were found in the experimental group and 2 (0.20%) in the comparison group, indicating
that increased hang time did not contribute to higher infection rates. Clinically, this research provided supportive evidence for health care administrators and providers who are
concerned about the safety of extending IV hang times and
are seeking guidance to support policy changes. This study

TABLE 2

Comparison of Patient-Related Variables
Hospital-based
variables

N

M

SD

Minimum

Maximum

Comparison

1048

7.43

8.08

1.00

72.00

Intervention

1919

6.71

7.13

1.00

71.00

Comparison

1048

54.46

18.82

16.00

101.00

Intervention

1919

53.16

19.06

15.00

98.00

Comparison

757

45.10

31.06

1.30

234.47b

Intervention

1376

44.68

28.34

1.03

219.65b

Z value

Length of stay
2.46a

Age at admittance
1.86 NS

IV hours
−0.26 NS

Abbreviations: IV, intravenous; NS, not significant.
a
P ≤ .05.
b
Patients were hospitalized for >1 week and had >1 IV. According to hospital policy, no single IV was hung for >96 hours, and the totals here reflect total number of hours
with an IV.
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TABLE 3

Cross-tabulations: Number of CLABSIs by Group Membership
Group
Intervention

Comparison

Total

CLABSIs

N

%

N

%

N

%

Infection – no

1914

99.7

1046

99.8

2960

99.8

Infection – yes

5

0.3

2

0.2

7

0.2

Total

1919

100

1048

100

2967

100

Abbreviation: CLABSI, central line-associated bloodstream infection.

examined what other researchers have not by comparing
the incidence of CLABSIs between increased hang times of
nonadditive IV solutions (up to 96 hours) and the standard
of care (hang times of ≤24 hours). The findings demonstrated that significant changes in the incidence of CLABSIs were
not evident. As a result, the current study provides support
to change the standard of care for hanging IV solutions up
to 96 hours in ICU and GPU practice settings.

STRENGTHS AND LIMITATIONS
The sample size of this study, 2967 patients, drawn from both
GPU and ICU practice settings, was large enough to be generalizable to similar adult practice unit populations. One limitation of the study is that there may have been more emphasis
on infection control or safe IV management after the intervention versus before the intervention. The change to 96
TABLE 4

Admitting Diagnoses
Group

Admitting Diagnosis

Number

ICU – intervention

Sepsis

9

GPU – intervention

28

ICU – comparison

4

GPU – comparison

25

Remainder of diagnoses were specific to group
Diagnosis by CLABSI
ICU – intervention

hours for IV hang time was announced by the CNO to unit
leadership and was based on shortages of solutions. The reasoning was made evident with emphasis on safe techniques,
which was standard practice. CLABSIs have also been tracked
in hospital-wide meetings on a daily basis for the last 5 years.
Data about patient admission and discharge diagnoses were
collected with the intent of identifying patients who were
more likely to develop CLABSIs. However, the abstracted data
revealed that many patients had multiple diagnoses and, in
total, >3900 different diagnoses combinations were attributed to the sample, which precluded additional analyses.

CONCLUSION AND IMPLICATIONS FOR
POLICY
Considering this study’s findings, in which increased hang
times of nonadditive IV solutions did not appear to contribute to increased incidence of CLABSIs, current hospital policy should reflect the safety of hanging nonadditive IV solutions for a period of up to 96 hours. Based on these results,
the policy for IV solution hang times was changed permanently at the hospital where the study was implemented.
Lengthened hang times of IV solutions would also synchronize with recommended hang times and replacement of
IV tubing administration sets (96 hours)7,8 and minimize
the risk of potential contamination that can occur when
IV delivery systems are unnecessarily broken to change
solutions. Nonadditive saline or dextrose IV solutions were
evaluated in this study with participants from both ICUs and
GPUs. This methodology contributes to the generalizability
of policy changes in similar health center populations.

Candidal sepsis

1

Diffuse large B-cell
lymphoma

1

ACKNOWLEDGMENT

Bloodstream infection

2

Antineoplastic
chemotherapy

1

The authors thank Catherine Draus, DNP, RN, for her contributions
to this study.

ICU – comparison

Postsurgical malabsorption

1

GPU – comparison

Hypertensive heart and
chronic kidney disease

1

GPU – intervention

Abbreviations: CLABSI, central line-associated bloodstream infection; GPU,
general practice unit; ICU, intensive care unit.
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